Synthetic Biologics, Inc.

Novartis Ag

Theriva Biologics, Inc.

Wellstat Immunotherapeutics, LLC

Synthetic Biologies, Inc.

Genetic Therapy, Inc.

Cell Genesys, Inc.

Genetic Theraphy, Inc.

Memorial Sloan Kettering Cancer Center

Novartis Pharma Gmbh

Pharma Cinq, LLC

Michael Kaleko

Sheila Connelly

Tianci Luo

Robert Berkowitz

Andrew Bristol

Vincent Wacher

Christian Furlan Freguia

Jeffrey Allan Miller

Beibei Li

Ruigong Wang

ChangHung Chen

Ivan Plavec

Janet Lynn Douglas

Steven Hubert

Peter Anthony Campochiaro

Romulus Kimbro Brazzell

J Blair West

Theodore Smith

Katharine Hilary Dixon

Shari Lynn Caplan

Brian R Boettcher

Jeffrey Allen Miller

Paul L Hallenbeck

Lori Clarke

Mario Gorziglia

John Leonard Jakubczak

Sandrina Phipps

Urvi J Desai

Eric D Slosberg

James Gubbins

Ray Stapleton

Cristina Freire

Jonathan Peled

Marina Burgos Da Silva

Changhung Chen

Marcel RM Van Den Brink

Vincent John Wacher

Vincent J Watcher

Blair J West

Robert David Berkowitz

The present invention relates to methods and compositions for preventing, treating, or reducing chemotherapy treatment-mediated side effects, including gastrointestinal (GI) side effects, comprising administering to a subject intestinal alkaline phosphatases (IAP).

Alkaline phosphate-based oncology treatments

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption from orally administered antibiotics.

Microbiome protection from oral antibiotics

The present invention provides, in part, formulations comprising a beta-lactamase. Particularly, modified-release formulations comprising a beta-lactamase are provided which release a substantial amount of the beta-lactamase in the intestines. Therapeutic uses of the beta-lactamase formulations are also provided.

Beta-lactamase formulations and uses thereof

The present invention provides, in part, formulations comprising an alkaline phosphatase (AP)-based agent. Particularly, modified-release powder formulations comprising an AP-based agent are provided which release a substantial amount of the AP-based agent in the intestines. Therapeutic uses of the formulations are also provided.

Alkaline phosphatase formulations

The invention relates to, in part, improved methods for the production of beta-lactamase using() cells. High yield production of beta-lactamase is achieved using methods of the invention.

-based production of beta-lactamase

This invention provides, in part, various compositions and methods for protecting the gastrointestinal microbiome from antibiotic disruption.

Method and compositions for inhibiting or preventing adverse effects of oral antibiotics

The present invention relates to, inter alia, compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of the effects of radiation exposure and/or chemotherapy.

Alkaline phosphatase agents for treatment of radiation disorders

The present invention provides for a formulation comprising an active alkaline phosphatase (AP)-based agent and an enteric agent, wherein the formulation is suitable for releasing a substantial amount of the active AP-based agent in the intestines.

Intestinal alkaline phosphatase formulations

This invention relates to, in part, compositions of beta-lactamases and methods of using these enzymes in, for example, gastrointestinal tract (GI tract) disorders such asinfection (CDI).

Beta-lactamases with improved properties for therapy

Compositions and methods, including therapeutic alkaline phosphatases that find use in the treatment or prevention of various neurodevelopmental diseases or disorders, are described.

Alkaline phosphatase agents for treatment of neurodevelopmental disorders

Growing community of inventors

Rockville, MD, United States of America

Michael Kaleko